Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Market News
Why these are the top performing ASX 200 shares over the past year
⏸️ TMF AMP
ASX 200 Weekly Wrap: Rocketing BNPL shares fail to stop ASX 200 slide
Share Gainers
These were the best performing ASX 200 shares last week
Share Market News
These 2 ASX medical shares are on the rise after major announcements
Share Market News
ASX 200 up 0.1%: Afterpay announces capital raising, big four banks lower ahead of RBA meeting
Share Market News
ASX 200 falls 0.7%, Qantas and Afterpay make a partnership
Share Gainers
Why the Mesoblast share price is leading the ASX 200 on Monday
Share Market News
ASX 200 edges higher: Afterpay and Qantas join forces, big four banks push higher
⏸️ Investing
Should you buy these 2 new ASX 200 index additions?
Share Gainers
These were the best performing ASX 200 shares in FY 2020
Share Market News
The top 10 performing ASX shares over the past year
Share Market News
ASX 200 drops 1.5% on elevated COVID-19 fears
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
